The report provides a detailed analysis essential for establishing a metyrapone production plant. It encompasses all critical aspects necessary for metyrapone production, including the cost of metyrapone production, metyrapone plant cost, metyrapone production costs, and the overall metyrapone production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a metyrapone production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Metyrapone is a diagnostic and therapeutic medicine that is mainly used to evaluate and manage disorders related to cortisol production. It is primarily utilised as a diagnostic tool in the diagnosis of adrenal insufficiency and certain pituitary disorders by testing the function of the pituitary gland and adrenal glands. It is used to assess adrenal gland function by measuring the body’s ability to produce cortisol. It works by blocking an enzyme involved in cortisol synthesis, which reduces the production of this hormone. It also finds application in the management of Cushing’s syndrome, where it is used to lower excessive cortisol levels in the body. In addition, it may also be used as a supportive treatment option in certain endocrine disorders. Additionally, it is often used in research studies focused on hormonal regulation and stress response.
The market for metyrapone is driven by its application as a specialised diagnostic and therapeutic agent for disorders related to cortisol production, which supports its demand in the medical sector. Its application in evaluating adrenal insufficiency by blocking cortisol production to measure hormone responses from the pituitary gland significantly promotes its demand in the endocrinology and healthcare industry. Its application in testing adrenal gland function and in the management of Cushing's syndrome, where excess cortisol causes health issues, also drives its demand in the medical and pharmaceutical industries.
Its usage as a part of endocrine testing procedures to manage hormonal issues also contributes to its demand in the medical and healthcare sectors. Its usage as a diagnostic aid in specialised treatment plans for patients with hormone-related conditions further drives its demand in the medical diagnosis and pharmaceutical industries. Manufacturing efficiency, supplier consistency, controlled production processes, and dependable global distribution networks also play a significant role in shaping the procurement decisions for metyrapone. Moreover, industrial metyrapone procurement is also influenced by various factors such as the cost and availability of active pharmaceutical ingredients, regulatory approvals, quality compliance, and safety standards.
Raw Material for Metyrapone Production
According to the metyrapone production plant project report, the major raw materials for metyrapone production include methyl 3-pyridyl ketone.
Production Process of Metyrapone
The extensive metyrapone production cost report consists of the following industrial production process:
- Production via Electrolytic Reduction: The production process of metyrapone begins with the electrolytic reduction of methyl 3-pyridyl ketone to form the corresponding pinacol, 2,3-bis(3-pyridyl)-2,3-butanediol. This step couples two ketone molecules under controlled electrochemical conditions to produce the diol intermediate. Then, the pinacol is heated with a strong inorganic acid, which causes dehydration followed by a rearrangement reaction that converts the diol into the desired metyrapone structure. After completion of the rearrangement, the crude product is purified by solvent crystallisation to obtain metyrapone in its final solid form.
Metyrapone is an aromatic ketone belonging to the class of steroidogenesis inhibitors, and it acts as a reversible inhibitor of the enzyme 11β-hydroxylase (CYP11B1). It appears as a pale beige to white crystalline solid that is sparingly soluble in water. The molecular formula of the compound is C14H14N2O, and its molar mass is 226.27 g/mol. Its density is approximately 1.12 g/cm³, and it is slightly soluble in water (less than 2 mg/mL) but readily soluble in methanol, DMSO, ethanol, and dilute mineral acids. The compound has a melting point in the range of 53-56 degrees Celsius and its boiling point is approximately 384.4 degrees Celsius at 760 mmHg.
The compound is classified as harmful if swallowed and is known to cause skin and eye irritation. It is recommended to handle metyrapone with appropriate protective equipment and store it at room temperature or at -20 degrees Celsius for long-term storage. Extended or improper use of this substance may cause adverse effects such as gastrointestinal distress, dizziness, headache, sedation, and allergic rash. It should not be administered during the second or third trimesters of pregnancy as it may impair steroid biosynthesis in the foetus.